Estimating In Vivo Fractional Contribution of OATP1B1 to Human Hepatic Active Uptake by Mechanistically Modeling Pharmacogenetic Data
A reasonable estimate on the fractional contribution of transporters to total hepatic active uptake (FT) is a critical factor in understanding and predicting human clearance, drug-drug interaction, and pharmacokinetic variability for hepatic transporter substrates. FT values for organic-anion-transporting polypeptide (OATP) 1B1 have been previously determined using in vitro assays. However, to date, none of the published in vitro FT values has been validated against or compared with in vivo FT values due to the lack of clinical data from selective substrates or inhibitors. The possible transporter-dependent in vitro to in vivo scaling further weakens the predictive power of these in vitro–determined FT values. In facing this challenge, a method is developed in this study to estimate in vivo OATP1B1 FT values by mechanistically modeling genotyped clinical pharmacokinetic data. The method is based on the hypothesis that observed change in hepatic active uptake clearance due to OATP1B1 polymorphism depends on two factors: (1) the contribution of OATP1B1 to the hepatic active uptake clearance and (2) the change of OATP1B1-mediated intrinsic uptake activity by the polymorphism. Conversely, if the changes caused by genetic variations in hepatic active uptake clearance and in OATP1B1-mediated clearance are known, then the OATP1B1 contribution to the hepatic active uptake clearance can be calculated. This is the first time that in vivo hepatic transporter FT values and a method to estimate these values are reported. Both FT values and the estimation method will facilitate future understanding and prediction on the transporter-mediated drug disposition.
KEY WORDSOATP1B1 fractional contribution hepatic transporter modeling and simulation pharmacogenetics
- 10.Yamada A, Maeda K, Kamiyama E, Sugiyama D, Kondo T, Shiroyanagi Y, et al. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos. 2007;35(12):2166–76.CrossRefGoogle Scholar
- 14.Bi YA, Qiu X, Rotter CJ, Kimoto E, Piotrowski M, Varma MV, et al. Quantitative assessment of the contribution of sodium-dependent taurocholate co-transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin. Biopharm Drug Dispos. 2013;34(8):452–61.CrossRefGoogle Scholar
- 16.Choi MK, Shin HJ, Choi YL, Deng JW, Shin JG, Song IS. Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors. Xenobiotica. 2011;41(1):24–34.CrossRefGoogle Scholar
- 29.Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics. 2004;14(7):429–40.CrossRefGoogle Scholar